trending Market Intelligence /marketintelligence/en/news-insights/trending/vAQgfoyzB7cUgi04tX9kFw2 content esgSubNav
In This List

US FDA rejects Coherus biosimilar drug

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


US FDA rejects Coherus biosimilar drug

The U.S. Food and Drug Administration rejected Coherus Biosciences' application to manufacture CHS-1701, a biosimilar version of Amgen Inc.'s Neulasta.

Neulasta helps in the growth of new white blood cells, which protects against the risk of infection following chemotherapy.

In its complete response letter, the regulator asked Coherus to reanalyze samples from a subset of patients for immunogenecity and sought additional manufacturing related process information.

Immunogenecity refers to the ability of a drug or vaccine to stir a response from the patient's immune system.

Coherus is also developing CHS-1420, a biosimilar version of Abbvie Inc.'s arthritis drug Humira, which passed a bioequivalence study in March.